Effect of tenofovir alafenamide on immune function and long-term prognosis in patients with chronic hepatitis B-related liver cirrhosis using two-dimensional ultrasound evaluation

and purpose : Chronic hepatitis B (CHB)-related cirrhosis is a chronic infectious disease caused by hepatitis B virus (HBV). This study evaluated the therapeutic effects of tenofovir alafenamide (TAF) on patients with CHB-related cirrhosis using two-dimensional ultrasound technology. One hundred and twenty-eight people with compensated CHB cirrhosis were randomly divided into ETV group (entecavir tablets) and TAF group (tenofovir alafenamide) and the treatment cycle was six months. Two-dimensional ultrasound was used to assess the portal vein diameter, splenic length, and splenic thickness of patients before treatment and six months after treatment. The comparisons in differences in blood routine, antiviral effect, liver function, immune function, and adverse reactions of the subjects were conducted, and a 3-year follow-up was conducted to compare the incidence of cirrhosis decompensation, liver cancer, and all-cause mortality. Compared with the ETV group, the ultrasound detection indicators portal vein diameter, splenic length, and splenic thickness after treatment, the serum levels of total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), laminin (LN), type III procollagen (PC-III), and type IV collagen (C-IV) were significantly decreased, while the liver stiffness measurement (LSM) and liver stiffness-spleen size-to-platelet ratio score (LSPS) score were significantly decreased in TAF group; Moreover, compared with the ETV group, the ratio of serum CD3 + , CD4 + , and CD4+/CD8+ were significantly increased, while the ratio of CD8 + was significantly decreased in TAF group; The decompensation rate of cirrhosis, hepatocellular carcinoma rate, and all-cause mortality in TAF group were significantly lower than the ETV group after follow-up (all P < 0.05). Based on ultrasound imaging evaluation, TAF can significantly enhance the antiviral effect and autoimmune function in CHB cirrhosis cases at the compensatory stage, and help the recovery of liver function and improve the long-term prognosis.